Goldhaber M K, Selby J V, Hiatt R A, Quesenberry C P
Division of Research Kaiser Permanente Medical Care Program, Oakland, California 94611.
Cancer Res. 1990 Aug 1;50(15):4600-3.
Barbiturate exposure during childhood was assessed from medical records of 237 children with intracranial and spinal cord tumors and 474 matched controls in a prepaid health plan. In utero exposure was also examined in a subset of 86 "cases" and 172 controls whose mothers were health plan members during pregnancy. No association of in utero exposure to barbiturates was found [odds ratio (O.R.) = 0.96, 95% confidence interval (C.I.) = 0.47, 1.94]. An association was noted for barbiturate use during childhood (O.R. = 1.80, 95% C.I. = 1.18, 2.74) but was reduced (O.R. = 1.41, 95% C.I. = 0.89, 2.21) when history of epilepsy was taken into account and was no longer significant. An apparent dose-response effect disappeared after adjustment for a history of epilepsy. Although barbiturate use for epilepsy due to preexisting brain tumors clearly explains some of the observed association, the small, residual risk prevents us from ruling out a possible carcinogenic effect of barbiturates. Further study of cohorts of adult as well as childhood users of barbiturates and other anticonvulsants is recommended.
通过一份预付健康计划中237名患有颅内和脊髓肿瘤的儿童以及474名匹配对照的医疗记录,评估儿童时期巴比妥类药物的暴露情况。在86名“病例”和172名对照的子集中还检查了子宫内暴露情况,这些病例和对照的母亲在怀孕期间是健康计划成员。未发现子宫内暴露于巴比妥类药物有相关性[比值比(O.R.)=0.96,95%置信区间(C.I.)=0.47,1.94]。注意到儿童时期使用巴比妥类药物有相关性(O.R. = 1.80,95% C.I. = 1.18,2.74),但在考虑癫痫病史后相关性降低(O.R. = 1.41,95% C.I. = 0.89,2.21)且不再显著。在对癫痫病史进行调整后,明显的剂量反应效应消失。虽然因先前存在的脑肿瘤而使用巴比妥类药物治疗癫痫显然可以解释部分观察到的相关性,但残留的小风险使我们无法排除巴比妥类药物可能的致癌作用。建议对巴比妥类药物和其他抗惊厥药物的成年及儿童使用者队列进行进一步研究。